Current Urology Reports

, 20:44 | Cite as

Emerging Treatments for Erectile Dysfunction: a Review of Novel, Non-surgical Options

  • Darshan P. Patel
  • Alexander W. Pastuszak
  • James M. HotalingEmail author
Men's Health (A Dabaja, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Men’s Health


Purpose of Review

To review novel, non-surgical therapies for erectile dysfunction (ED).

Recent Findings

Recently, a landmark study identified the SIM1 locus, involved in the leptin-melanocortin pathway, as an independent risk factor for ED and a potential target for novel therapies. The recent literature otherwise has focused on low-intensity shock wave therapy (LiSWT), with several randomized trials and meta-analyses suggesting therapeutic efficacy.


There are few novel oral agents for ED. There is growing evidence suggesting efficacy of intracavernosal stem cells therapy and low-intensity shock wave therapy (LiSWT), although these therapies are still investigational. A better understanding of the pathophysiologic spectrum of ED will offer new opportunities for novel, non-surgical therapies for ED.


Erectile dysfunction Sexual dysfunction Physiological Dietary supplement Platelet-rich plasma Genetic therapy Extracorporeal shockwave therapy 


Compliance with Ethical Standards

Conflict of Interest

Darshan P. Patel declares no potential conflicts of interest.

Alexander W. Pastuszak reports advisor, speaker, consultant, and research and fellowship support from Endo Pharmaceuticals; is an advisor for Boston Scientific and Antares Pharmaceuticals; and holds a leadership position with Woven Health.

James M. Hotaling reports a research and fellowship grant from Endo Pharmaceuticals and a fellowship grant from Boston Scientific; and holds leadership positions with Nanonc, SteamDx, and Andro360.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND). Trials Circulation. 2010;121(12):1439–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Schouten BW, Bohnen AM, Bosch JL, Bernsen RM, Deckers JW, Dohle GR, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res. 2008;20(1):92–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766–78.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Batty GD, Li Q, Czernichow S, Neal B, Zoungas S, Huxley R, et al. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol. 2010;56(23):1908–13.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Kirby M. The circle of lifestyle and erectile dysfunction. Sex Med Rev. 2015;3(3):169–82.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423–32 This recent guideline provides a comprehensive review of the evaluation and treatment of testosterone deficiency.PubMedCrossRefGoogle Scholar
  11. 11.
    •• Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–41 This recent guideline provides a comprehensive review of the evaluation and treatment of ED.PubMedCrossRefGoogle Scholar
  12. 12.
    Wessells H, Joyce GF, Wise M, Wilt TJ. Erectile dysfunction. J Urol. 2007;177(5):1675–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Lal S, Laryea E, Thavundayil JX, Nair NP, Negrete J, Ackman D, et al. Apomorphine-induced penile tumescence in impotent patients--preliminary findings. Prog Neuro-Psychopharmacol Biol Psychiatry. 1987;11(2–3):235–42.CrossRefGoogle Scholar
  14. 14.
    Heaton JP. Key issues from the clinical trials of apomorphine SL. World J Urol. 2001;19(1):25–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Von Keitz AT, Stroberg P, Bukofzer S, Mallard N, Hibberd M. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int. 2002;89(4):409–15.CrossRefGoogle Scholar
  16. 16.
    Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem. 2004;47(15):3853–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int J Impot Res. 2000;12(Suppl 4):S74–9.PubMedCrossRefGoogle Scholar
  18. 18.
    •• Jorgenson E, Matharu N, Palmer MR, Yin J, Shan J, Hoffmann TJ, et al. Genetic variation in the SIM1 locus is associated with erectile dysfunction. Proc Natl Acad Sci U S A. 2018;115(43):11018–23 This recent landmark study identified a genetic association between a SIM1 locus and ED. This genome-wide association study provides targets for other gene discoveries and novel ED therapies.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med. 2013;10(5):1268–77.PubMedCrossRefGoogle Scholar
  20. 20.
    Guagnini F, Ferazzini M, Grasso M, Blanco S, Croci T. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med. 2012;10:59.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Chaitoff A, Killeen TC, Nielsen C. Men’s health 2018: BPH, prostate cancer, erectile dysfunction, supplements. Cleve Clin J Med. 2018;85(11):871–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159(2):433–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Lebret T, Herve JM, Gorny P, Worcel M, Botto H. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol. 2002;41(6):608–13 discussion 13.PubMedCrossRefGoogle Scholar
  24. 24.
    Klotz T, Mathers MJ, Braun M, Bloch W, Engelmann U. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int. 1999;63(4):220–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Jang DJ, Lee MS, Shin BC, Lee YC, Ernst E. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol. 2008;66(4):444–50.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Choi J, Kim TH, Choi TY, Lee MS. Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. PLoS One. 2013;8(4):e59978.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Shindel AW, Xin ZC, Lin G, Fandel TM, Huang YC, Banie L, et al. Erectogenic and neurotrophic effects of icariin, a purified extract of horny goat weed (Epimedium spp.) in vitro and in vivo. J Sex Med. 2010;7(4 Pt 1):1518–28.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Anaissie J, Hellstrom WJ. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Res Rep Urol. 2016;8:123–31.PubMedPubMedCentralGoogle Scholar
  29. 29.
    •• Gu X, Hua S, Ethan M, Zhong L, Long T, Clouse C, et al. Long-term therapeutic effect of cell therapy on improvement in erectile function in a rat model with pelvic neurovascular injury. BJU international. 2018. This recent study demonstrates therapeutic efficacy of intracavernosal stem cell injection in an animal model. Normal saline (control), umbilical vein endothelial cells, adipose-derived stem cells, and amniotic fluid-derived stem cells were injected into the corpus cavernosum of rats. The authors show a significant increase in the intracavernosal pressure/mean arterial pressure ratio in treated rats compared with controls.Google Scholar
  30. 30.
    Bivalacqua TJ, Champion HC, Mehta YS, Abdel-Mageed AB, Sikka SC, Ignarro LJ, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res. 2000;12(Suppl 3):S8–17.PubMedCrossRefGoogle Scholar
  31. 31.
    Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C, Taylor BK, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol. 2007;292(3):H1278–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol. 2003;169(5):1911–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Johnston EK, Francis MK, Knepper JE. Recombinant pigment epithelium-derived factor PEDF binds vascular endothelial growth factor receptors 1 and 2. In Vitro Cell Dev Biol Anim. 2015;51(7):730–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Gettins PG, Simonovic M, Volz K. Pigment epithelium-derived factor (PEDF), a serpin with potent anti-angiogenic and neurite outgrowth-promoting properties. Biol Chem. 2002;383(11):1677–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Chen X, Yang Q, Zheng T, Bian J, Sun X, Shi Y, et al. Neurotrophic effect of adipose tissue-derived stem cells on erectile function recovery by pigment epithelium-derived factor secretion in a rat model of cavernous nerve injury. Stem Cells Int. 2016;2016:5161248.PubMedGoogle Scholar
  36. 36.
    Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58(2):243–8.PubMedCrossRefGoogle Scholar
  37. 37.
    •• Campbell JD, Trock BJ, Oppenheim AR, Anusionwu I, Gor RA, Burnett AL. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. Ther Adv Urol. 2019;11:1756287219838364 This recent meta-analysis of randomized trials suggests therapeutic efficacy of LiSWT for ED.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. J Sex Med. 2017;14(1):27–35.PubMedCrossRefGoogle Scholar
  39. 39.
    Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71(2):223–33.PubMedCrossRefGoogle Scholar
  40. 40.
    Katz JE, Molina ML, Clavijo R, Prakash NS, Ramasamy R. A phase 2 randomized trial to evaluate different dose regimens of low-intensity extracorporeal shockwave therapy for erectile dysfunction: clinical trial update. Eur Urol Focus. 2018;4(3):336–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013;9(12):721–30.PubMedCrossRefGoogle Scholar
  42. 42.
    Akeda K, Yamada J, Linn ET, Sudo A, Masuda K. Platelet-rich plasma in the management of chronic low back pain: a critical review. J Pain Res. 2019;12:753–67.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Marck RE, Middelkoop E, Breederveld RS. Considerations on the use of platelet-rich plasma, specifically for burn treatment. J Burn Care Res. 2014;35(3):219–27.PubMedCrossRefGoogle Scholar
  44. 44.
    Hesseler MJ, Shyam N. Platelet-rich plasma and its utility in medical dermatology - a systematic review. J Am Acad Dermatol. 2019.Google Scholar
  45. 45.
    Wu CC, Wu YN, Ho HO, Chen KC, Sheu MT, Chiang HS. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med. 2012;9(11):2838–48.PubMedCrossRefGoogle Scholar
  46. 46.
    • Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investigative and clinical urology. 2018;59(1):61–5 This study assesses the safety and feasibility of PRP for ED.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Darshan P. Patel
    • 1
  • Alexander W. Pastuszak
    • 1
  • James M. Hotaling
    • 1
    Email author
  1. 1.Division of Urology, Department of SurgeryUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations